CG Oncology (CGON) shares rose 14.0% to $84.78 on Monday, November 16, 2026, after the company said its Phase 3 PIVOT-006 trial of cretostimogene met its primary endpoint. The company said cretostimogene resulted in a 68% reduction in the risk of recurrence compared with the control arm.
What happened
CG Oncology announced the topline results in a press release on November 16 and furnished the release to the SEC with a Form 8-K. The SEC filing index shows the 8-K was accepted at 8:15 a.m. that day.
The release describes cretostimogene as an investigational, intravesically delivered oncolytic immunotherapy. PIVOT-006 tested it in patients with intermediate risk and high grade Ta non muscle invasive bladder cancer (NMIBC) after complete tumor resection. The trial enrolled 367 patients across about 90 sites in the United States and Canada, and compared cretostimogene with surveillance.
The company said there were no Grade 3 or greater treatment related adverse events and no treatment related discontinuations. It said there are currently no FDA approved adjuvant treatment options for this population of approximately 50,000 patients.
The numbers
- Close: $84.78, up 14.0% from $74.40 on November 13 (Nasdaq data)
- Reduction in the risk of recurrence: 68%, with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p less than 0.0001) (press release)
- Median follow up: 17 months as of October 26, 2026 (press release)
- Planned application: a second Biologics License Application (BLA), in intermediate risk and high grade Ta NMIBC, anticipated in the second quarter of 2027 (press release)
Context
The company also announced updated timing for its first BLA, in BCG unresponsive NMIBC, according to the Form 8-K. Based on FDA feedback, that submission will be broadened to include high grade papillary only disease, and the company anticipates completing it in March 2027.
The release says the PIVOT-006 topline results will be presented at the Society of Urologic Oncology Annual Meeting on December 2, 2026. Cretostimogene has received FDA Fast Track and Breakthrough Therapy designations for BCG unresponsive NMIBC. Its safety and efficacy have not been established by the FDA or any other health authority, the company said.


